Inhibitors of phosphatidic acid phosphohydrolase (PAP), including D-propranolol and analogs thereof, alone or in combination with desipramine, for the treatment of cancers that depend on the epidermal growth factor receptor (EGFR), oncogenic variants thereof and other members of the ErbB/HER family
The present invention describes the use of compounds and combinations thereof which inhibit the phosphatidic acid phosphohydrolase enyzme (PAP) for producing medicines that can be used to treat cancer； PAP inhibitors are used to block the progression of cancers that depend on the epidermal growth factor receptor (EGFR), oncogenic variants thereof and other members of the ErbB family, by inducing the endocytosis thereof and thus making them inaccessible to stimuli which promote cancer survival and progression； the PAP inhibitors which are part of the invention include drugs which are currently used for other clinical purposes and which are not connected apart from the fact that they are cationic amphiphilic molecules； these include propranolol, desipramine and chlorpromazine, drugs which are used for other clinical purposes； the present invention covers all PAP inhibitors, including sphingosine and bromoenol lactone and any new inhibitors which may be discovered in the future.
